Complement-Mediated Kidney Disorders: A Case Series
Three case studies exploring complexities of diagnosing, treating, and managing patients with various complement-mediated kidney disorders.
Related Articles
Efficacy of Atrasentan To Treat Patients With IgA Nephropathy
Richard Lafayette, MD, discusses the recent approval of Vanrafia (atrasentan) for patients with IgA nephropathy (IgAN).
Digital Voice Analysis as a Biomarker of Acromegaly
A recent study published in the JCEM analyzed the use of digital voice analysis as a biomarker of acromegaly.
Complement-Mediated Kidney Disorders: A Case Series
Three case studies exploring complexities of diagnosing, treating, and managing patients with various complement-mediated kidney disorders.
New FDA-Approved C3 Glomerulopathy (C3G) Treatment Targets Underlying Cause of Disease
Carla Nester, MD, discusses the recent U.S. FDA approval of iptacopan as the first and only treatment of adults with C3 glomerulopathy (C3G).
FORWARD-53 Clinical Trial in Duchenne Muscular Dystrophy Shows Promise
Paul Bolno, MD, discusses results from the FORWARD-53 clinical trial evaluating WVE-N531 in patients with DMD amenable to exon 53 skipping.
Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx
A recent study evaluated outcomes of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) patients treated with R-GemOx.
Long-term Efficacy of TransCon PTH to Treat Hypoparathyroidism
A new study highlights the safety and long-term efficacy of TransCOn PTH (palopegteriparatide) to treat hypoparathyroidism.
Atypical Autosomal Dominant Polycystic Kidney Disease With IFT140 Variants
This study focuses on 75 patients with ADPKD-like phenotypes with 41 different monoallelic predicted loss-of-function IFT140 variants.
First Treatment (Diazoxide Choline) Approved for Hyperphagia in Prader-Willi Syndrome
Ashley Shoemaker, MD, discusses the first treatment approved for Prader-Willi syndrome and associated hyperphagia, diazoxide choline
Watch the DAYBUE® (trofinetide) in Practice Video Series to Hear Expert Insights on the First Treatment for This Rare Disease
Rett syndrome thought leaders discuss how DAYBUE™ (trofinetide), the first and only FDA-approved treatment for Rett syndrome in adults and pediatric patients 2 years of…